<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>C4 Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/c4-therapeutics-inc</link>
<description>Latest news and press releases for C4 Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/c4-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683552eb78dffbe2df0e83ec.webp</url>
<title>C4 Therapeutics Inc</title>
<link>https://6ix.com/company/c4-therapeutics-inc</link>
</image>
<item>
<title>C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-expands-long-term-partnership-with-roche-through-new-collaboration-agreement-focused-on-discovering-and-developing-degrader-antibody-conjugates-dacs</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-expands-long-term-partnership-with-roche-through-new-collaboration-agreement-focused-on-discovering-and-developing-degrader-antibody-conjugates-dacs</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload</description>
</item>
<item>
<title>C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-first-patient-dosed-in-phase-1b-trial-of-cemsidomide-in-combination-with-elranatamab-elrexfior-for-relapsedrefractory-multiple-myeloma</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-first-patient-dosed-in-phase-1b-trial-of-cemsidomide-in-combination-with-elranatamab-elrexfior-for-relapsedrefractory-multiple-myeloma</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc.</description>
</item>
<item>
<title>C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple</description>
</item>
<item>
<title>C4 Therapeutics to Participate in Upcoming March Conferences</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-to-participate-in-upcoming-march-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-to-participate-in-upcoming-march-conferences</guid>
<pubDate>Mon, 23 Feb 2026 12:10:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences. TD Cowen 46th Annual Healthcare Conference: Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts. Barclays 28th Annual Global Hea</description>
</item>
<item>
<title>C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-first-patient-dosed-in-phase-2-momentum-trial-of-cemsidomide-an-oral-ikzf13-degrader-in-combination-with-dexamethasone-for-relapsedrefractory-multiple-myeloma</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-first-patient-dosed-in-phase-2-momentum-trial-of-cemsidomide-an-oral-ikzf13-degrader-in-combination-with-dexamethasone-for-relapsedrefractory-multiple-myeloma</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate</description>
</item>
<item>
<title>C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-participate-guggenheim-emerging-120000652</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-participate-guggenheim-emerging-120000652</guid>
<pubDate>Wed, 04 Feb 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY. Fireside Chat Details:Date: Wednesday, February 11, 2026 Time: 11:30 AM ET A live webcast will be available</description>
</item>
<item>
<title>C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-inducement-grant-210100993</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-inducement-grant-210100993</guid>
<pubDate>Mon, 26 Jan 2026 21:01:00 GMT</pubDate>
<description>WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”)</description>
</item>
<item>
<title>C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-outlines-strategic-milestones-120000990</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-outlines-strategic-milestones-120000990</guid>
<pubDate>Wed, 14 Jan 2026 12:00:00 GMT</pubDate>
<description>Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points WATERTOWN, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) -</description>
</item>
<item>
<title>C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-participate-8th-annual-120000407</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-participate-8th-annual-120000407</guid>
<pubDate>Tue, 25 Nov 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida. Fireside Chat Details:Event: 8th Annual Evercore Healthcare ConferenceDate/Time: Wednesday, December 3rd, 2025 at</description>
</item>
<item>
<title>C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-third-quarter-120000313</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-third-quarter-120000313</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomid</description>
</item>
<item>
<title>C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-pricing-125-110800169</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-pricing-125-110800169</guid>
<pubDate>Thu, 16 Oct 2025 11:08:00 GMT</pubDate>
<description>$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today an</description>
</item>
<item>
<title>C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-clinical-trial-110000089</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-announces-clinical-trial-110000089</guid>
<pubDate>Wed, 01 Oct 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phas</description>
</item>
<item>
<title>C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-presents-cemsidomide-phase-150000359</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-presents-cemsidomide-phase-150000359</guid>
<pubDate>Sat, 20 Sep 2025 15:00:00 GMT</pubDate>
<description>Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations Related to Cemsidomide and Few Dose Reductions Support a Safety Pro</description>
</item>
<item>
<title>C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-highlights-recent-achievement-110000309</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-highlights-recent-achievement-110000309</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>Development Candidate Targeting IRAK4 Now Progressing Toward Clinical DevelopmentWATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to</description>
</item>
<item>
<title>C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-present-data-phase-110000960</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-present-data-phase-110000960</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>C4T to Host Webcast on September 20, 2025 at 3 pm ETWATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET</description>
</item>
<item>
<title>Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/akamis-bio-announces-the-appointment-of-andrew-hirsch-to-the-companys-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/akamis-bio-announces-the-appointment-of-andrew-hirsch-to-the-companys-board-of-directors</guid>
<pubDate>Tue, 12 Aug 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., August 12, 2025--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic payloads to solid tumors, today announced the appointment of Andrew Hirsch, MBA, to the Company’s Board of Directors.</description>
</item>
<item>
<title>C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-second-quarter-110000021</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-second-quarter-110000021</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which Is</description>
</item>
<item>
<title>C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-first-quarter-110000317</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-first-quarter-110000317</guid>
<pubDate>Wed, 07 May 2025 11:00:00 GMT</pubDate>
<description>Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 Portfolio Deci</description>
</item>
<item>
<title>C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-fourth-quarter-120000607</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-reports-fourth-quarter-120000607</guid>
<pubDate>Thu, 27 Feb 2025 12:00:00 GMT</pubDate>
<description>Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 T</description>
</item>
<item>
<title>C4 Therapeutics to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-participate-upcoming-march-120000594</link>
<guid isPermaLink="true">https://6ix.com/company/c4-therapeutics-inc/news/c4-therapeutics-participate-upcoming-march-120000594</guid>
<pubDate>Mon, 24 Feb 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences. TD Cowen 45th Annual Healthcare Conference: Management will present on March 3rd at 9:10 am ET in Boston, MA. The live webcast will be available on the Events & Presentations page of the company’s websit</description>
</item>
</channel>
</rss>